Ovasave: Phase IIb amended

TxCell amended the double-blind, placebo-controlled, European Phase IIb CATS29 trial to now evaluate a single IV injection of

Read the full 184 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE